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A B S T R A C T
Antimicrobials have been commonly used to control bacterial diseases in farm animals. The efficacy of these
drugs deterred the development of other control measures, such as vaccines, which are currently getting more
attention due to the increased concern about antimicrobial resistance. Glässer’s disease is caused by Glaesserella
(Haemophilus) parasuis and affects pork production around the world. Balance between colonization and im-
munity seems to be essential in disease control. Reduction in antimicrobial use in veterinary medicine requires
the implementation of preventive measures, based on alternative tools such as vaccination and other strategies
to guarantee a beneficial microbial colonization of the animals. The present review summarizes and discusses the
current knowledge on diagnosis and control of Glässer’s disease, including prospects on alternatives to anti-
microbials.
1. Introduction
Since the discovery of antimicrobials, bacterial diseases have been
commonly controlled by using these drugs. The effectiveness of anti-
microbials resulted in the development and use of vaccines against
these infections becoming a lesser priority. In veterinary medicine, the
lag in the development of efficient vaccines against bacterial diseases is
even more striking than in human medicine (main commercial bacterial
vaccines used in veterinary medicine are listed in Table 1). However,
the increased concern about antimicrobial resistance is promoting the
research in efficient vaccines and vaccine use.1
Pork represents about 36% of the total meat produced worldwide
(FAO meat market report 2018). Pig production is present in all con-
tinents, with China, the EU and the USA producing more than 90 mil-
lion tons of pork in 2018 (FAO meat market report 2018). Health is one
of the most important contributors to productivity, profitability and
animal welfare in pig production today. Glässer’s disease remains a
significant economic burden for the pig industry, with major impact in
the nursery and early fattening stages. Acute outbreaks of Glässer’s
disease can cause high mortality (typically between 5–10% in young
animals), together with high costs due to productive impairments,
carcass disposal and associated treatments (http://www.nadis.org.uk/
bulletins/glaessers-disease.aspx). Moreover, G. parasuis typically com-
plicates infections by other primary pathogens, such as influenza virus
or porcine reproductive and respiratory syndrome (PRRS) virus, wor-
sening the production parameters. Unfortunately, the precise burden of
disease, as well as the contribution of different risk factors to Glässer’s
disease development, have not been fully quantified.
Although the use of antimicrobials continues to be a common means
to treat this infection, the economic impact of the disease for pig pro-
duction can also be inferred by vaccine sales. The market for Glässer’s
disease licensed monovalent vaccines in Europe was estimated to be of
€7M, and over €15M globally on 2018; with a trend to increase in
countries with highly restricted use of antimicrobials (HIPRA, un-
published data). In addition, awareness on the emergence of anti-
microbial resistance presses for the implementation of alternatives for
disease control. Antimicrobial resistance (AMR) is a serious threat to
animal and public health, and international policies are demanding a
reduction in their use, especially in the farming industry (https://amr-
review.org). Although global efforts to reduce the use of antimicrobials
in pig farming have been adopted internationally, compensatory stra-
tegies for disease control are still needed.
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2. Pathogenesis of Glässer’s disease
Haemophilus parasuis, recently renamed Glaesserella parasuis after
detailed phylogenetic analysis (Dickerman et al., 2019), is a Gram-ne-
gative bacterium of the Pasteurellaceae family, which is present in most
commercial pig farms as an early colonizer of piglets. In fact, the bac-
terium can be detected in the nasal cavity of piglets as soon as 2 days
after birth (Cerdà-Cuéllar et al., 2010). However, the onset of Glässer’s
disease occurs later, after weaning, normally linked to situations of
stress along with a decrease in maternal immunity (Aragon et al.,
2019).
2.1. Diversity of G. parasuis strains and pathogenesis of disease
G. parasuis is a heterogeneous bacterial species that comprises
strains with wide differences in virulence (Kielstein and Rapp-
Gabrielson, 1992; Aragon et al., 2010). Non-virulent strains are con-
sidered part of the normal nasal microbiota of piglets, while virulent
strains are considered primary pathogens and the cause of Glässer’s
disease (Aragon et al., 2019). This duality needs to be considered when
diagnosing and controlling the disease. Classically, G. parasuis strains
have been classified into 15 serovars, some of them associated to
virulence (Kielstein and Rapp-Gabrielson, 1992). Serovars 4 and 5 are
the most commonly reported from clinical cases, but serovars 2, 12, 13,
14 and 15 are also frequently isolated (Castilla et al., 2012; Zhang et al.,
2012).
Comparisons between virulent and non-virulent strains of G. para-
suis have allowed the description of some mechanisms of pathogenesis
of this bacterium. G. parasuis is able to colonize mucosae by adhering to
the mucus layer and the underlying epithelium (Bouchet et al., 2009;
Frandoloso et al., 2012; Bello-Orti et al., 2014). Virulent and non-
virulent strains can be detected in the upper respiratory tract, but dif-
ferences in colonization capacity are revealed in their progression to the
lower respiratory tract. Once in the trachea, virulent strains demon-
strate higher colonization capacity (Bello-Orti et al., 2014). G. parasuis
virulence is associated to evasion of the innate immune system by de-
gradation of IgA (Mullins et al., 2011), resistance to phagocytosis by
alveolar macrophages (Olvera et al., 2009) and resistance to serum
complement (Cerdà-Cuéllar and Aragon, 2008). Thus, virulent strains
survive in the lung, while non-virulent strains are cleared by the action
of phagocytes, mainly alveolar macrophages (Olvera et al., 2009; Bello-
Orti et al., 2014). Virulent G. parasuis can subsequently spread sys-
temically, causing a strong inflammation, which together with the
disruption of adherens junctions and increased vascular permeability,
result in considerable fibrin exudates (Costa-Hurtado et al., 2013; Hua
et al., 2018). These processes can explain the characteristic findings of
fibrinous polyserositis observed in Glässer’s disease.
2.2. Factors affecting disease onset
Although G. parasuis is endemic in most pig farms, Glässer’s disease
is only observed in some cases. Some risk factors affecting disease de-
velopment, common to other diseases in swine, are the environmental
conditions of the facilities, stress, management practices and concurrent
presence of other pathogens (Pereira et al., 2017). Exacerbation of
clinical signs and lesions by co-infections with G. parasuis and viruses,
such as swine influenza virus or/and PRRS virus are well known by
clinical practitioners, but also supported by experimental data showing
stronger deleterious inflammatory responses in co-infections (Li et al.,
2017b; Pomorska-Mol et al., 2017). These viral infections disturb the
pig immune response, increasing the likelihood of developing disease,
even by G. parasuis strains with low pathogenic potential (Olvera et al.,
2009).
Specific risk factors for Glässer’s disease include the immunity
against G. parasuis, which will be discussed later, and the virulence of
the strains circulating in the farm. In fact, the presence of virulent
strains in the nasal cavity of pigs constitutes a risk factor for the de-
velopment of disease, while colonization by non-virulent strains may
confer protection against subsequent exposure to virulent strains, and
therefore against disease (Brockmeier et al., 2013). Colonization by G.
parasuis can also be driven by other factors, such as medication, vac-
cination and sow parity. Moreover, the global composition of the nasal
microbiota at weaning has been found to influence the later develop-
ment of Glässer’s disease (Correa-Fiz et al., 2016). As also reported for
other maladies, a lower diversity in the nasal microbiota at weaning
was associated with higher risk of suffering Glässer’s disease in the
nursery (Correa-Fiz et al., 2016). Taking this observation into account,
factors negatively affecting bacterial diversity, such as the use of pre-
ventive antimicrobials, may have the opposite effect, triggering the
development of disease.
3. Diagnosis
3.1. Clinical and pathological diagnosis
Diagnosis of Glässer’s disease starts at the farm with the observation
of clinical signs, followed by a pathological diagnosis. Clinical signs of
Glässer’s disease are non-specific and include fever, cough, abdominal
breathing, swollen joints and lameness, as well as signs of central
nervous system impairment such as lateral decubitus, pedaling and
tremors (Aragon et al., 2019). Piglets with acute disease show char-
acteristic lesions of fibrinous polyserositis, and occasionally purulent
catarrhal pneumonia, at postmortem examination (Aragon et al., 2019).
Chronically affected animals may show reduced growth and fibrinous
polyserositis lesions at necropsy (Aragon et al., 2019). Clinical and
pathological observations need to be always complemented with la-
boratory confirmation of the aetiological agent, to rule out other pa-
thogens that can cause similar gross lesions, such as Streptococcus suis or
Mycoplasma hyorhinis (Aragon et al., 2019).
3.2. Laboratory diagnosis
Detection of the pathogen is commonly achieved by bacterial iso-
lation and molecular detection by PCR (Angen et al., 2007). Although
PCR speeds up diagnosis, bacterial isolation is recommended when
supplemental characterization of the strains is necessary, such as anti-
microbial susceptibility. As mentioned previously, not all the G. parasuis
strains have the same ability to cause disease. Characterization of the
pathogenic potential of an isolate is a complex process that involves in
vitro and in vivo virulence tests. While this obviously cannot be done in
routine diagnosis, this information has been important for the design of
Table 1
Main commercial bacterial vaccines used in swine medicine.
Disease Bacterial agent
Respiratory Enzootic pneumonia Mycoplasma hyopneumoniae
Atrophic rhinitis Bordetella Bronchiseptica,
Pasteurella multocida D
Porcine pleuropneumonia Actinobacillus pleuropneumoniae
Pasteurellosis Pasteurella multocida A + D
Reproductive Leptospirosis Leptospira sp.
Digestive Neonatal diarrhoea Escherichia coli (enterotoxigenic)
Clostridium perfringens
Colibacillosis Escherichia coli (enterotoxigenic)
Proliferative enteropathy Lawsonia intracellularis
Salmonellosis Salmonella Typhimurium




Glässer’s disease Glaesserella (Haemophilus) parasuis
Swine erysipelas Erysipelothrix rhusiopathiae
Edema (Oedema) disease Escherichia coli (verotoxigenic)
Streptococcal infection Streptococcus suis
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molecular tests, together with analysis of the strains’ genomes. It should
be noted that PCR tests are now available to determine the serovar and
pathogenic capacity of strains of G. parasuis (see below).
3.3. Samples for diagnosis
The culture of G. parasuis in the laboratory is not always successful.
It is convenient to collect samples from more than one animal with clear
symptoms of the disease and not treated with antibiotics. If the lesions
are systemic, the sampling should include all those organs that may be
involved in the symptoms, such as the brain, joints and serous surfaces.
A high number of samples increases the possibility of detecting this
fastidious bacterium. Samples from the respiratory tract are proble-
matic, since colonizing strains, which may include non-virulent strains,
could be aspirated to the lung during euthanasia. Thus, lung samples
should only be taken in the event of pneumonia and from distal parts
(lungs and distal bronchioles). It is also crucial to prevent contamina-
tion of the samples by using an aseptic method and ensure a fast
transport to the laboratory under refrigeration (4−8 °C). Particularly,
in the case of swabs, Amies transport medium is recommended to
preserve viability of the bacteria (del Rio et al., 2003).
3.4. Antimicrobial susceptibility testing
Antimicrobial therapy needs to be preceded by determination of the
antimicrobial susceptibility of the clinical isolate. Standard methods
and specific breakpoints for G. parasuis have not been established yet.
Recently, some efforts have been made in the harmonization of the
broth microdilution susceptibility test (Brogden et al., 2018; Prüller
et al., 2016). Information on the minimal inhibitory concentration
(MIC) values will result in a more educated decision for treatment.
3.5. PCR associated with virulence and molecular serotyping
The situation in the farm is usually complex, where is common to
find diverse strains infecting concurrently the same population of pigs
(Cerdà-Cuéllar et al., 2010). Isolation of bacteria from systemic lesions
is an indication of the virulence of the strain, as the capacity to pene-
trate systemically has been described as a virulence trait. However, this
cannot be assumed for samples in the respiratory tract, because G.
parasuis has been isolated in the slaughterhouse on bronchi (3.5%
prevalence) and lungs (2% prevalence) from animals without clinical
signs of pneumonia (Palzer et al., 2008).
Serovar determination can be useful for vaccine selection, and
molecular serotyping has become a major advance in G. parasuis diag-
nosis (Howell et al., 2015). Molecular serotyping is easy to standardize
and implement and has been able to significantly reduce the number of
non-typeable strains reported by immunological methods. However, the
congruency of results with antigenic serotyping is not total and further
validation with more strains will be useful (Ma et al., 2016).
The possibility of differentiating virulent from non-virulent strains
has improved radically the diagnosis of the disease. Genomic analyses
have generated information for the design of simple molecular tests for
identification of strains with higher virulence potential. Several genes
have been proposed as virulence markers and tested with reference and
field strains (Galofre-Mila et al., 2017; Turni et al., 2018). Recently the
leader sequences of the virulence-associated trimeric autotransporter
(vtaA) genes have been used to predict the virulence of strains by PCR
(Galofre-Mila et al., 2017). Although the association of this PCR with
virulence was demonstrated, further analysis with more field strains is
required for complete validation of the technique (Turni et al., 2018).
In addition, in agreement with the multifaceted nature of the patho-
genicity of G. parasuis, a more complex PCR has been developed to
detect a set of genes whose presence was associated with the clinical
origin of the strain (Howell et al., 2017). These PCRs designed to detect
virulent strains could be used in nasal samples to assess carriers of
virulent strains and evaluate the risk of developing Glässer’s disease on
each farm.
4. Control
Three key elements in the control Glässer’s disease are herd man-
agement, use of antimicrobials and immunization by vaccination. Since
sows are the only known source of the bacterium, they need to be in-
cluded in control programs.
4.1. Herd management
Some stressful practices such as early weaning, transportation, in-
adequate temperatures or air draught, among others, have been de-
scribed to cause immunosuppression and trigger the disease onset if
virulent bacteria are present (Pereira et al., 2017). Hence, efforts should
be done to achieve management practices that minimize stressful si-
tuations, particularly on the weaning phase.
4.2. Antimicrobial therapy
Antimicrobials are extensively used for the control of bacterial
diseases in pigs, including Glässer’s disease. However, such use is clo-
sely related to an increase of antimicrobial resistance, which is cur-
rently one of the world’s biggest concerns in terms of animal and public
health. Mitigation of this problem relies on a prudent use of anti-
microbials, while effective alternatives to combat bacterial diseases,
especially for veterinary medicine, are scarce. The need to reduce the
use of antimicrobials is central to many health policies in both human
and veterinary medicine.
The world organization for animal health (OIE) standards provide
global recommendations for controlling antimicrobial resistance, in-
cluding lists of antimicrobial agents of veterinary importance to treat
animal diseases. In parallel, the world health organization (WHO) has
also developed a list of critically important antimicrobial agents in
human medicine. The overlap of critical lists for human and veterinary
medicine leads to guidelines, such as the European 2015/C 299/04, for
more restricted antimicrobial interventions for a sustainable pig pro-
duction.
When antimicrobials are used to treat Glässer’s disease, treatment
should start as soon as the first clinical signs are observed, since usually,
pigs treated early during infection are able to recover. However, field
data indicate that antimicrobial treatment can select resistant strains of
G. parasuis, and can lead to drug and multidrug resistance in G. parasuis
isolates (Table 2 and Fig. 1). It is particularly concerning that, for ex-
ample, two out of three antibiotics for which resistance was recently
detected in more than 50% of the Spanish isolates (flumequine and
neomycin; Fig. 1) are classified on the Spanish national AMR surveil-
lance plan (PRAN) as category 2 (2nd choice or last resort use in ve-
terinary medicine) and categorized by the WHO as Critically Important
of priority 1 and 2.
Antimicrobial resistance has been also detected in nasal isolates
from healthy pigs (Moleres et al., 2015; Zhang et al., 2019). This finding
highlights the importance of colonizing strains as reservoir of drug re-
sistance; even more if we consider that some resistance genes in G.
parasuis could be mobilized by plasmids (Li et al., 2015; Moleres et al.,
2015; Zhang et al., 2018).
Antimicrobials can also hinder the development of an effective
protective immune response against future infections by virulent G.
parasuis (Macedo et al., 2017). The use of antimicrobials around the
time of colonization of the upper respiratory tract can interfere with the
colonization by G. parasuis, and importantly with the onset of immunity
and posterior protection of the piglets (Macedo et al., 2017). This in-
terference is not limited to G. parasuis, but it also influences the rest of
the microbiota (Correa-Fiz et al., 2019). When perinatal antimicrobials
are removed from piglets, higher bacterial diversity in the nasal
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microbiota is observed, which has been linked to a better health status
and well-being (Correa-Fiz et al., 2019). Antimicrobials have detri-
mental effects on healthy microbiota communities, and its early use in
piglets induces a reduced bacterial diversity that causes a poorer per-
formance of the immune system (Schokker et al., 2014; Correa-Fiz
et al., 2019). Reduction in the use of antimicrobials, especially when
treating piglets in a metaphylactic manner, should be a priority in pig
production. Improvement in biosecurity and feed quality, as well as
increase in the use of vaccines have been identified as promising al-
ternatives to antimicrobials in industrial pig farming (Postma et al.,
2015; Collineau et al., 2017).
To sum up, strategic antimicrobial treatments may only be advised
on a few limited situations, mainly to treat piglets during a disease
outbreak, which is important not only for health but also for welfare
issues. Alternative control measures should be taken to minimize the
potential increase of Glässer’s disease caused by resistant G. parasuis.
4.3. Vaccination
4.3.1. Role of antibodies in protection
G. parasuis is part of the nasal microbiota. Newborn piglets are co-
lonized upon contact with the sows during lactation, while receiving
maternally derived antibodies through the colostrum, establishing a
balance between colonization and immunity. G. parasuis is an extra-
cellular pathogen, hence the humoral immune response (antibodies)
plays an essential role in protection against disease (Nedbalcova et al.,
2011). Antibodies against G. parasuis opsonize bacteria for subsequent
detection and uptake by alveolar macrophages for killing (Olvera et al.,
2009). Opsonization by antibodies seems to have less impact in com-
plement killing (Cerdà-Cuéllar and Aragon, 2008), but the role of spe-
cific antibodies in serum susceptibility cannot be ruled out, as observed
with sera obtained from pigs experimentally vaccinated or infected
(Brockmeier et al., 2013). Strikingly, piglets with low antibody levels
(considered negative as measured by commercial ELISA-INgezim Hae-
mophilus) and with no detectable nasal colonization by G. parasuis, as
detected by PCR, can be resistant to infection by a highly virulent strain
(V. Aragon, unpublished observations). This may be explained by the
presence of antibodies that are not detected in the ELISA used or by the
existence of other mechanisms of protection.
4.3.2. Types of vaccines and their limitations
Most of the G. parasuis vaccines that are commercially available
nowadays are inactivated and serovar-specific, with limited cross-pro-
tection against all pathogenic serovars (reviewed in Liu et al., 2016). It
is generally acknowledged that they are efficacious against homologous
serovars through the production of high levels of opsonizing antibodies.
However, homologous protection against the most frequent serovars, 4
and 5, has been reported to rank from full to none (Takahashi et al.,
2001; Bak and Riising, 2002), indicating that, even within the same
serovar, strains may differ in antigenicity. Therefore, strains to be used
in commercial vaccines should be selected carefully. Literature on
cross-protection is divergent, but cross-protection against serovars 4
and 5 with heterologous vaccines has been reported in some occasions
(Liu et al., 2016; Zhao et al., 2017). Some commercial vaccines include
more than one serovar in the formulation to enhance cross-protection.
Moreover, the adjuvant of choice has been found to be important to
increase efficacy, especially when the product contains multiple anti-
gens (Xue et al., 2015). Still, when using inactivated vaccines, pigs
require multiple immunizations to generate long-term protection (Liu
et al., 2016). In some occasions, autogenous vaccines containing the G.
parasuis strains present in the farm are used. These vaccines present
some drawbacks, such as variable and usually lower concentration of
antigen, uncertain safety since verification is not required by regula-
tions, and difficulties in ascertain that the correct strains are included in
the composition (Kirkwood et al., 2001; Liu et al., 2016). Moreover,
some of the modern adjuvants are proprietary, and therefore are not
available for the preparation of this type of autogenous vaccines.
Subunit vaccines contain specific antigenic molecules of G. parasuis,
which may lead the immune response towards common epitopes pre-
sent in pathogenic strains. This type of vaccines would not affect the
beneficial non-virulent strains from the microbiota, which in fact might
have protective effects (Brockmeier et al., 2013). Up to now, there is no
commercial subunit vaccines to prevent Glässer’s disease, but multiple
experimental subunit vaccines have shown protection in the pig model
(Olvera et al., 2011; Fu et al., 2013; Frandoloso et al., 2015; McCaig
et al., 2016; Guizzo et al., 2018). Studies to examine the heterologous
protection of the vaccine candidates are still needed. The type of ad-
juvant is also expected to be essential in vaccine design as it can
modulate differently the immune response to the same antigen
(Barasuol et al., 2017).
The design of subunit vaccines frequently relays on the identifica-
tion of putative surface exposed or secreted molecules, by im-
munoproteomics in combination with genome sequencing (Martinez-
Martinez et al., 2013; Li et al., 2017a). Subsequent successful re-
combinant expression, good protein yield for mass production, and
adequate protein folding are some of the challenges to be faced. Recent
recombinant proteins identified as highly immunoreactive: proteins
HxuC, HxuB, TolC, LppC, and HAPS_0926 (Wen et al., 2016; Li et al.,
2017c); Omp16 (Zheng et al., 2017); superoxide dismutase (Guo et al.,
2017); and HbpA, OppA, HPS-04307, AfuA, and HktE (Li et al., 2017a),
have shown protection in mice against lethal challenge with G. parasuis.
These results need to be confirmed in the pig model, since some
Fig. 1. Antimicrobial resistance of Glaesserella
(Haemophilus) parasuis field strains isolated in
HIPRA DIAGNOS laboratory between the years
2014 and 2017. Results are expressed as per-
centage of resistant (black bars), sensitive
(white bars) and intermediate (gray bars) iso-
lates (N = 57) to the following antimicrobials:
florfenicol 30 μg (FFC), sufametoxazole-trime-
troprim 25 μg (SXT), doxycycline 30 μg (DO),
tetracycline 30 μg (TE), enrofloxacin 5 μg
(ENF), amoxicillin 25 μg (AML), flumequine 30
μg (UB), gentamycin 10 μg (CN), neomycin 10
μg (N), colistin 10 μg (CT), ceftiofur 30 μg
(CEFT). Antimicrobial categories based on
Spanish Action Plan on Antimicrobial
Resistance: Cat. 0, antimicrobials not included
in any category since alternatives are available to treat serious human diseases and their use is not consider risky for the emergence and dissemination of resistances;
Cat. 1, antibiotics used in veterinary medicine on a regular basis and as 1st choice but they have recommendations of use since they are critically important for
human health; Cat. 2, antibiotics that should be used in veterinary medicine as 2nd choice and/or last resort for being antimicrobials critically important for human
health (Cat. 3 corresponds to antimicrobials not permitted in veterinary medicine).
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recombinant proteins showing protection in the mouse model failed to
protect pigs (Alvarez-Estrada et al., 2018).
The identification of specific epitopes is key to design a targeted
immune response against virulent G. parasuis. The surface expose F4
fragment, common to VtaAs of virulent strains (Correa-Fiz et al., 2017),
portions of the loops of the neuraminidase (Bregon-Villahoz et al.,
2017) or fragments of transferring binding proteins (TbpAB)
(Frandoloso et al., 2011) are some examples of promising candidates.
However, further research is needed to identify common epitopes and
to prove heterologous protection in the pig model.
Full understanding of the virulence factors associated with G.
parasuis infection will be key to improving vaccines; e.g. vaccines to
enhance mucosal immunity and block the early steps of infection in the
upper respiratory tract, would further limit the spread to internal or-
gans. Additional considerations for vaccine design, such as the short
window available for piglet vaccination, impulse the development of
one-shot vaccines, possibly through research on new safe effective ad-
juvants for neonates or different routes of vaccination.
4.3.3. Maternal immunity and sow vaccination
The prevalence of Glässer’s disease is higher in nursery piglets, and
therefore management, including vaccination, should be directed to
wean protected piglets (Aragon et al., 2019). Piglets are colonized by G.
parasuis while getting protective colostrum from their dams. Maternally
derived antibodies (MDA) decrease during lactation to low titters at
weaning, which is commonly performed at 3–4 weeks of age (Cerdà-
Cuéllar et al., 2010). The window for piglet vaccination is short, and
therefore sow vaccination may be considered. There is not a complete
agreement on the interference of the MDA with piglet vaccination
against G. parasuis. While some studies report no effective interference
when vaccinating piglets with two doses (Oh et al., 2013), other studies
report an interference effect after sow vaccination that precluded piglet
vaccination effect (Pomorska-Mol et al., 2011). This might indicate that
interference could be associated to the level of MDA in the colostrum. It
is worth mentioning that the use of different vaccines and serological
tests in previously published studies, could also account for part of the
differences in the level of interference observed. A particular case is the
vaccination of naïve gilts, since this would provide protection not only
to the piglets but also to the gilts themselves when facing farms with
high G. parasuis pressure. Thus, vaccination of gilts against G. parasuis
can be considered part of the gilt acclimation program.
Colonization at weaning is a key element that could be beneficial to
avoid subsequent Glässer’s disease in the farms (Correa-Fiz et al., 2016).
However, there is no consensus on the influence of MDA on nasal co-
lonization. Brean et al. (2016) found that litters of primiparous sows
were colonized earlier by G. parasuis than those of multiparous sows, in
agreement with the lower maternal immunity expected in gilts. How-
ever, other authors have reported higher isolation of G. parasuis from
the nasal cavities of 2 week old piglets from multiparous sows, while
none of the piglets from primiparous were positive (Kirkwood et al.,
2001). When sow vaccination is considered, contradictory results have
been reported. While Kirkwood et al. (2001) found no effect of sow
vaccination on G. parasuis colonization of piglets, Cerdà-Cuéllar et al.
(2010) found that sow vaccination delayed the colonization of piglets,
reduced the bacterial load and the heterogeneity of G. parasuis strains.
Nonetheless, sow vaccination may be effective to protect piglets during
lactation, but, as mentioned before, lasting protection may require
vaccination of piglets after the farrowing phase, together with actions
to ensure an early colonization.
Altogether, to make the best decisions at the farm level, it may be
useful to examine the serological profile of the herd to design of a
suitable vaccination program to reduce MDA interference with piglet
vaccination. In this way, higher protection rates could be achieved at
the time of greatest risk of disease development (Pomorska-Mol et al.,
2011).
4.4. Nasal microbiota
Recent studies on the nasal microbiota of piglets have revealed the
role of this microbiota in predisposition to Glässer’s disease (Correa-Fiz
et al., 2016). Several genera, for example from the Bacteroidetes and
Firmicutes phyla, were associated with health, supporting the possibility
of mining the microbiota for health promotion. In addition, elimination
of perinatal antimicrobials can increase the nasal microbiota diversity,
which was also linked to health (Correa-Fiz et al., 2016, 2019). More-
over, the microbiota not only can promote resistance to pathogens but
can also provide an stimulation of the immune system for an enhanced
vaccine response (Lynn and Pulendran, 2018), pointing towards pos-
sible dual strategies as co-adjuvant in new vaccine formulations. These
results open a new direction for disease control in swine by modulation
of the nasal microbiota, promoting the elimination of metaphylactic
antimicrobial treatments.
5. Final remarks
In this global context of antibiotic restriction, good management,
biosecurity strategies and tailored vaccination programs targeting
virulent strains of G. parasuis appear to be key elements to consider in
Glässer’s disease control. Maternal antibody levels and nasal coloniza-
tion by G. parasuis non-virulent strains and other beneficial bacteria
need to be also taken into account. Effective control of disease will need
of a holistic approach, integrating the above-mentioned elements, along
with effective diagnosis of the pathogenic potential and antigenic
properties of the G. parasuis strains. Finally, if antimicrobials are
needed, susceptibility tests to antimicrobials should be performed be-
fore the use of these drugs, whose use should be limited and with the
narrowest spectrum of action possible.
Synergies between industry and research institutions will open the
door to new opportunities, such as vaccine design with broader het-
erologous protection, which would lead to the future of a cost-effective,
responsable and sustainable farming.
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